In Flemingsberg, we cure diseases that were previously considered incurable

Earlier this year we hosted the most meaningful ATMP event of the spring, in collaboration with Miltenyi Biotec and the Karolinska ATMP Center, Karolinska University Hospital and Karolinska Institutet. We gathered over 120 participants, all sharing a vision of creating momentum to accelerate access to ATMPs in the Nordics.

”It’s fantastic, it’s a great opportunity to learn more about what’s going on at Karolinska and for the whole ATMP environment. From the Pre GMP to the manufacturing, to then the clinical trials that they offer here, and I think that’s one of the things that are really unique about the whole Flemingsberg ATMP ecosystem” – Jonathan Clarke, Development Manager at SmartCella.

During the event we launched ATMP Flemingsberg, a platform that encapsulates all the expertise within ATMP in Flemingsberg, from research to clinical implementation.

”We have everything in Flemingsberg and you can see that because they come here from Uppsala and other parts of the world to manufacture their products and do their treatments here” – Ewa Ellis, ATMP coordinator at Karolinska University Hospital.

The seminar shed light on Pre-GMP and GMP, as well as how to advance one’s process to the next level and how Vecura can assist in scaling up. Additionally, Stefan Mielke, an expert in the field, discussed equal access and emphasized the importance of collaborative efforts to make therapies more accessible to patients. Di Yu from Elicera Therapeutics also shared their journey, which began at Vecura in Flemingsberg.

“Clinical trials are very important because they bring innovation to our patients. For those of you who don’t know what CAR-T cells are, they are like glasses for T-cells, so that they can see tumor cells.” – Stephan Mielke, Professor and Scientific Director of the Cancer Center.

Watch our film below, summarizing our successful event. Together, we can accelerate access to ATMPs in the Nordics.

Visit atmpflemingsberg.se

*ATMP (Advanced Therapy Medicinal Products) också kallade Avancerade terapiläkemedel är baserade på celler, vävnader eller gener och delas in i tre huvudkategorier: somatiska cellterapier, genterapier och vävnadstekniska produkter.

Fresh start for flooring that reduces fall injuries

A new flooring technology can drastically reduce fall injuries among the elderly. Rubber spikes activate in the event of a sudden impact and can prevent, for example, femoral fractures. The technology is based on KTH research and was initially developed with the support of the Kraftcentrum Flemingsberg program.

ANA Futura further strengthens Campus Flemingsberg

ANA Futura is officially inaugurated at Campus Flemingsberg – a unique research environment focused on bringing down boundaries: boundaries between research and education, as well as between academia and the community.

New multi-million kronor agreement for Sprint Bioscience

Sprint Bioscience and LG Chem have signed a cooperation and licensing agreement for research, development and commercialization of drug candidates. “We’re delighted about the agreement with LG Chem, an ideal partner to further develop this programme,” says Dr Anders Åberg, Sprint Bioscience CEO.

Go to Top